Functional Analysis of the Effects of Propofol on Tamoxifen‑resistant Breast Cancer Cells: Insights into Transcriptional Regulation

Overview

Journal Oncol Lett

Specialty Oncology

Date 2025 Mar 5

PMID 40041408

Authors

Runyang Yin

Jing Gao

Yang Liu

Chunyan Guo

Affiliations

Soon will be listed here.

Abstract

Although 70% of patients with estrogen receptor-positive breast cancer benefit from tamoxifen (TAM) therapy, the development of resistance to TAM leads to high rates of metastasis and a poor prognosis. Propofol, a commonly used anesthetic, can inhibit the occurrence and progression of breast cancer. In the present study, the effects of propofol on TAM-resistant (TR) breast cancer cells were evaluated. MCF7-TR cells were treated with or without propofol. Subsequently, cell cycle progression and the induction of apoptosis were detected by flow cytometry, whereas cell proliferation was assessed using Cell Counting Kit-8 and colony formation assays. Furthermore, the potential transcriptional regulatory effects of propofol on MCF7-TR cells were investigated using RNA sequencing. The results indicated that propofol significantly promoted cell cycle arrest, induced apoptosis, and inhibited proliferation and colony formation in MCF7-TR cells. Furthermore, transcriptome sequencing analysis revealed 1,065 differentially expressed genes between propofol-treated MCF7-TR and untreated MCF7-TR cells. Gene Ontology annotation enrichment analysis, Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis and Gene Set Enrichment Analysis indicated that propofol affected the expression levels of genes located on the 'plasma membrane' and 'cell periphery', while mainly regulating signals involved in cancer biology, immune response and metabolic pathways. These results identified the potential effects of propofol on TR breast cancer cells and provided a theoretical basis for clinical treatment, particularly for individuals with TAM resistance.

References

Moon S, Kim H, Lee Y, Lee Y, Jung S, Lee J . Oncogenic signaling pathways and hallmarks of cancer in Korean patients with acral melanoma. Comput Biol Med. 2023; 154:106602. DOI: 10.1016/j.compbiomed.2023.106602. View

Salvati A, Melone V, Sellitto A, Rizzo F, Tarallo R, Nyman T . Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer. Breast Cancer Res. 2022; 24(1):52. PMC: 9290241. DOI: 10.1186/s13058-022-01547-7. View

Sasada S, Kondo N, Hashimoto H, Takahashi Y, Terata K, Kida K . Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer. Breast Cancer Res Treat. 2023; 202(3):473-483. PMC: 10564809. DOI: 10.1007/s10549-023-07097-6. View

Lee H, Lee J, Song I, Park I, Kang J, Yu J . Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. Breast Cancer Res Treat. 2015; 151(3):619-27. DOI: 10.1007/s10549-015-3438-8. View

Liu H, Wang N, Yang R, Luan J, Cao M, Zhai C . E3 Ubiquitin Ligase NEDD4L Negatively Regulates Skin Tumorigenesis by Inhibiting IL-6/GP130 Signaling Pathway. J Invest Dermatol. 2024; 144(11):2453-2464.e11. DOI: 10.1016/j.jid.2024.03.030. View

Muller M, Burmeister A, Skowron M, Stephan A, Bremmer F, Wakileh G . Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights. Clin Epigenetics. 2022; 14(1):5. PMC: 8742467. DOI: 10.1186/s13148-021-01223-1. View

Icard P, Shulman S, Farhat D, Steyaert J, Alifano M, Lincet H . How the Warburg effect supports aggressiveness and drug resistance of cancer cells?. Drug Resist Updat. 2018; 38:1-11. DOI: 10.1016/j.drup.2018.03.001. View

Hanker A, Sudhan D, Arteaga C . Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 2020; 37(4):496-513. PMC: 7169993. DOI: 10.1016/j.ccell.2020.03.009. View

Zhu Y, Zhang H, Pan C, He G, Cui X, Yu X . Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancer. Cancer Med. 2022; 12(5):5846-5858. PMC: 10028167. DOI: 10.1002/cam4.5372. View

10.

Chen F, Wang L, Feng Y, Ma W, Liu J, Bi Q . F-box and leucine-rich repeat protein 16 controls tamoxifen sensitivity via regulation of mitochondrial respiration in estrogen receptor-positive breast cancer cells. Hum Cell. 2023; 36(6):2087-2098. DOI: 10.1007/s13577-023-00961-z. View

11.

Goncalves T, de Araujo L, Ferrer V . Tamoxifen as a modulator of CXCL12-CXCR4-CXCR7 chemokine axis: A breast cancer and glioblastoma view. Cytokine. 2023; 170:156344. DOI: 10.1016/j.cyto.2023.156344. View

12.

Cao Z, Jin Z, Zeng L, He H, Chen Q, Zou Q . Prognostic and tumor-immune infiltration cell signatures in tamoxifen-resistant breast cancers. Gland Surg. 2021; 10(9):2766-2779. PMC: 8514308. DOI: 10.21037/gs-21-566. View

13.

Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger P . Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle. 2010; 9(4):689-99. DOI: 10.4161/cc.9.4.10611. View

14.

Malekmohammadi M, Price C, Hudson A, DiCesare J, Pouratian N . Propofol-induced loss of consciousness is associated with a decrease in thalamocortical connectivity in humans. Brain. 2019; 142(8):2288-2302. PMC: 6931391. DOI: 10.1093/brain/awz169. View

15.

Zhang J, Liu F, Guo W, Bi X, Yuan S, Shayiti F . Single-cell transcriptome sequencing reveals aberrantly activated inter-tumor cell signaling pathways in the development of clear cell renal cell carcinoma. J Transl Med. 2024; 22(1):37. PMC: 10775677. DOI: 10.1186/s12967-023-04818-9. View

16.

Li Q, Jiang B, Guo J, Shao H, Del Priore I, Chang Q . INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer Discov. 2021; 12(2):356-371. PMC: 8831444. DOI: 10.1158/2159-8290.CD-20-1726. View

17.

Kim J, Munster P . Estrogens and breast cancer. Ann Oncol. 2024; 36(2):134-148. DOI: 10.1016/j.annonc.2024.10.824. View

18.

Jiang C, Zhu Y, Chen H, Lin J, Xie R, Li W . Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer. Cell Death Dis. 2023; 14(10):653. PMC: 10558541. DOI: 10.1038/s41419-023-06181-5. View

19.

Wang H, Zhao L, Wu J, Hong J, Wang S . Propofol induces ROS-mediated intrinsic apoptosis and migration in triple-negative breast cancer cells. Oncol Lett. 2020; 20(1):810-816. PMC: 7285815. DOI: 10.3892/ol.2020.11608. View

20.

Zhang X, Li F, Zheng Y, Wang X, Wang K, Yu Y . Propofol Reduced Mammosphere Formation of Breast Cancer Stem Cells via PD-L1/Nanog . Oxid Med Cell Longev. 2019; 2019:9078209. PMC: 6393877. DOI: 10.1155/2019/9078209. View